ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Bibliographic Details
Main Authors:	Segelov, Eva, Waring, Paul, Desai, Jayesh, Wilson, Kate, Gebski, Val, Thavaneswaran, Subotheni, Elez, Elena, Underhill, Craig, Pavlakis, Nick, Chantrill, Lorraine, Nott, Louise, Jefford, Michael, Khasraw, Mustafa, Day, Fiona, Wasan, Harpreet, Ciardiello, Fortunato, Karapetis, Chris, Joubert, Warren, van Hazel, Guy, Haydon, Andrew, Price, Tim, Tejpar, Sabine, Tebbutt, Niall, Shapiro, Jeremy
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886432/

id	pubmed-4886432
recordtype	oai_dc
spelling	pubmed-48864322016-06-01 ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours Segelov, Eva Waring, Paul Desai, Jayesh Wilson, Kate Gebski, Val Thavaneswaran, Subotheni Elez, Elena Underhill, Craig Pavlakis, Nick Chantrill, Lorraine Nott, Louise Jefford, Michael Khasraw, Mustafa Day, Fiona Wasan, Harpreet Ciardiello, Fortunato Karapetis, Chris Joubert, Warren van Hazel, Guy Haydon, Andrew Price, Tim Tejpar, Sabine Tebbutt, Niall Shapiro, Jeremy Study Protocol BioMed Central 2016-05-31 /pmc/articles/PMC4886432/ /pubmed/27246726 http://dx.doi.org/10.1186/s12885-016-2389-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Segelov, Eva Waring, Paul Desai, Jayesh Wilson, Kate Gebski, Val Thavaneswaran, Subotheni Elez, Elena Underhill, Craig Pavlakis, Nick Chantrill, Lorraine Nott, Louise Jefford, Michael Khasraw, Mustafa Day, Fiona Wasan, Harpreet Ciardiello, Fortunato Karapetis, Chris Joubert, Warren van Hazel, Guy Haydon, Andrew Price, Tim Tejpar, Sabine Tebbutt, Niall Shapiro, Jeremy
spellingShingle	Segelov, Eva Waring, Paul Desai, Jayesh Wilson, Kate Gebski, Val Thavaneswaran, Subotheni Elez, Elena Underhill, Craig Pavlakis, Nick Chantrill, Lorraine Nott, Louise Jefford, Michael Khasraw, Mustafa Day, Fiona Wasan, Harpreet Ciardiello, Fortunato Karapetis, Chris Joubert, Warren van Hazel, Guy Haydon, Andrew Price, Tim Tejpar, Sabine Tebbutt, Niall Shapiro, Jeremy ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
author_facet	Segelov, Eva Waring, Paul Desai, Jayesh Wilson, Kate Gebski, Val Thavaneswaran, Subotheni Elez, Elena Underhill, Craig Pavlakis, Nick Chantrill, Lorraine Nott, Louise Jefford, Michael Khasraw, Mustafa Day, Fiona Wasan, Harpreet Ciardiello, Fortunato Karapetis, Chris Joubert, Warren van Hazel, Guy Haydon, Andrew Price, Tim Tejpar, Sabine Tebbutt, Niall Shapiro, Jeremy
author_sort	Segelov, Eva
title	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
title_short	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
title_full	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
title_fullStr	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
title_full_unstemmed	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
title_sort	icecream: randomised phase ii study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either kras, nras, braf and pi3kca wild type, or g13d mutated tumours
description
publisher	BioMed Central
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886432/
_version_	1613586430981832704

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Similar Items